Work

Xylazine’s κ relatively potent opioid agonist activity is not shared with other US Food and Drug Administration-approved α2-adrenergic agonists

Year: 2026

Type: article

Source: Journal of Pharmacology and Experimental Therapeutics

DOI: 10.1016/j.jpet.2026.104969

Authors: Xi-Ping Huang, Brian E. Krumm, Madigan L. Bedard, Zoe A. McElligott, Bryan L. Roth

Institutions: University of North Carolina at Chapel Hill, National Institute of Mental Health

Language: English

Topic: Receptor Mechanisms and Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Health and Human Services, National Institutes of Health, University of North Carolina at Chapel Hill, National Institute of Mental Health

Awards: An informatics approach to examine genetic and environmental regulation of the PI3K-AKT-mTOR pathway in autism spectrum disorder, G8691474425

OpenAlex ID: W7165365757

FWCI:

Cites: 32

Cited by:

Related to: 10